<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5176">
  <stage>Registered</stage>
  <submitdate>4/09/2015</submitdate>
  <approvaldate>4/09/2015</approvaldate>
  <nctid>NCT02564718</nctid>
  <trial_identification>
    <studytitle>Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates</studytitle>
    <scientifictitle>7-day Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children From Birth to Less Than 6 Months With Arterial or Venous Thrombosis</scientifictitle>
    <utrn />
    <trialacronym>Einstein Jr</trialacronym>
    <secondaryid>2014-002385-74</secondaryid>
    <secondaryid>17618</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Thromboembolism</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Rivaroxaban(Xarelto,BAY59-7939)

Experimental: Arm 1 - Rivaroxaban oral suspension from granules will be dosed according to body weight as oral 0.1% suspension (1 mg/mL)


Treatment: drugs: Rivaroxaban(Xarelto,BAY59-7939)
Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venour thromboembolism (VTE) with 20 mg once daily.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>plasma concentration of rivaroxaban - To measure the concentration of rivaroxaban at various time points</outcome>
      <timepoint>Day 1- 8</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>rivaroxaban protime (PT) - To obtain a baseline and then determine the effect of rivaroxaban on the prothrombin time</outcome>
      <timepoint>Day 1- 8</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>activated partial thromboplastin time (aPPT) - To obtain a baseline and then determine the effect of rivaroxaban on the activated partial thromboplastin time</outcome>
      <timepoint>Day 1- 8</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>anti-factor Xa activity(anti-Xa) activity in the course of time after rivaroxaban dosing - To determine the effect of rivaroxaban on the anti-Xa activity</outcome>
      <timepoint>Day 1-8</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of major bleeding - To determine the frequency and severity of major bleeding in this age population while taking rivaroxaban</outcome>
      <timepoint>At day 1-7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of clinically relevant non-major bleeding - To determine the frequency and severity of clinically relevant non-major bleeding in this age population while taking rivaroxaban</outcome>
      <timepoint>At day 1-7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of symptomatic recurrent thromboembolism - To determine the frequency and severity of symptomatic recurrent thromboembolism in this age population while taking rivaroxaban</outcome>
      <timepoint>At day 1-7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of asymptomatic deterioration in thrombotic burden on repeat imaging - To determine the change in thrombotic burden comparing the repeat imaging with the baseline imaging test after 8 days of rivaroxaban.</outcome>
      <timepoint>At day 8</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Children from birth to less than 6 months with documented symptomatic or asymptomatic
             venous or arterial thrombosis who have been treated with anticoagulant therapy for at
             least 5 days.

          -  Gestational age at birth of at least 37 weeks.

          -  Hemoglobin, platelets, creatinine, ALT and total and direct bilirubin assessed within
             10 days prior to enrollment.

          -  Oral feeding/nasogastric/gastric feeding for at least 10 days.

          -  Informed consent provided.

          -  Body weight &gt;2600 g</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>6</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Active bleeding or high risk for bleeding contraindicating anticoagulant therapy,
             including history of intra-ventricular bleeding.

          -  Symptomatic progression of thrombosis during preceding anticoagulant treatment.

          -  Planned invasive procedures, including lumbar puncture and removal of nonperipherally
             placed central lines during study treatment.

          -  Hepatic disease which is associated with either: coagulopathy leading to a clinically
             relevant bleeding risk, or alanine aminotransferase (ALT) &gt; 5x upper level of normal
             (ULN) or total bilirubin (TB) &gt; 2x ULN with direct bilirubin &gt; 20% of the total.

          -  Creatinine &gt;1.5 times of normal.

          -  Uncontrolled Hypertension defined as &gt;95th percentile.

          -  History of gastrointestinal disease or surgery associated with impaired absorption.

          -  Platelet count &lt;100 x 109/L.

          -  Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 (CYP3A4)
             and P-glycoprotein (P-gp), e.g. all human immunodeficiency virus protease inhibitors
             and the following azole-antimycotics agents: ketoconazole, itraconazole, voriconazole,
             posaconazole, if used systemically (fluconazole is allowed)

          -  Concomitant use of strong inducers of CYP3A4, e.g. rifampicin, rifabutin,
             phenobarbital, phenytoin and carbamazepine

          -  Indication for anticoagulant therapy other than current thrombosis.

          -  Indication for antiplatelet therapy or non-steroid anti-inflammatory drug (NSAID)
             therapy. Incidental use is allowed.

          -  Hypersensitivity to rivaroxaban or its excipients.

          -  Participation in a study with an investigational drug or medical device within 30 days
             prior to enrollment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Other</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>19/11/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>8</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>2/01/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital> - Parkville</hospital>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Steiermark</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Tampere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bayern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hessen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein-Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>AFula</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat Gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Piemonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Veneto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nijmegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>A Coruña</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Vaud</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zürich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Janssen Pharmaceuticals Inc</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to find out whether rivaroxaban is safe and effective to use in
      children age newborn to less than 6 months and how long it stays in the body and how it is
      used in the body. Safety will be assesed by looking at the incidence and types of bleeding
      events. There will also be a check for worsening of blood clots.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02564718</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bayer Study Director</name>
      <address>Bayer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Bayer Clinical Trials Contact</name>
      <address />
      <phone>1-888-84-22937</phone>
      <fax />
      <email>clinical-trials-contact@bayer.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>